Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for neurological, psychiatric, endocrine, and immunological disorders. The company's value proposition is centered on addressing significant unmet medical needs through a portfolio of approved treatments and a diversified pipeline of small molecules and biologics. Its primary revenue driver is a leading treatment for tardive dyskinesia and Huntington's disease chorea.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Commercial Products
primaryThe company's revenue-generating division focused on the marketing and sale of FDA-approved therapies for movement disorders and endocrine conditions. These products are distributed primarily through specialized specialty pharmacy networks and wholesale channels.
INGREZZA (valbenazine), CRENESSITY (crinecerfont), DYSVAL (valbenazine), REMLEAS (valbenazine), ORILISSA (elagolix), ORIAHNN (elagolix, estradiol, and norethindrone acetate)
Specialty pharmacy providers, Wholesale distributors, Specialty distributors
Clinical Development Pipeline
minorA robust research and development segment focused on advancing a multi-modal pipeline from early-phase discovery to late-stage clinical trials. This segment targets prevalent central nervous system disorders and rare orphan diseases using small molecules, peptides, and gene therapies.
Osavampator (NBI-1065845), Direclidine (NBI-1117568), NBI-1117570, NBI-1117569, NBI-1065890, NBI-1140675, NBI-1076986, NBI-1117567, NBI-921355, NBIP-01435, NBIP-2118
Clinical trial participants, Research institutions
Segment Financials
Collaboration revenues — Total revenues
View metricReportable Segment — R&D
View metricReportable Segment — Cost of revenues
View metricReportable Segment — Acquired in-process research and development
View metricBusiness Overview
Competitive Position
A leading neuroscience company with the first FDA-approved treatment for tardive dyskinesia and a dominant position in the VMAT2 inhibitor market.
Geographies
United States, Japan, Asia
Customer Segments
Patients, Healthcare Providers, Specialty Pharmacies
Upstream Dependencies
Third-party contract manufacturers (CMOs), Active pharmaceutical ingredient (API) suppliers, Third-party logistics providers
Downstream Customers
Specialty pharmacies, Pharmaceutical wholesalers, Hospitals and long-term care facilities, Endocrinology and neurology clinics
Competitors & Partners
Partners
AbbVie
ABBV
Collaboration partner for elagolix in endometriosis and uterine fibroids
Takeda Pharmaceutical Company Limited
TAK
Licensing partner for osavampator (NBI-1065845)
Nxera Pharma UK Limited
Licensing partner for direclidine (NBI-1117568)
Xenon Pharmaceuticals
XENE
Licensing partner for NBI-921355
Sentia Medical Sciences, Inc.
Internal discovery collaboration for novel peptide CRF receptor antagonists
Tanabe Pharma Corporation
Commercialization partner for valbenazine in Japan and select Asian markets
Neurocrine Biosciences FAQ
Common questions about Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for neurological, psychiatric, endocrine, and immunological disorders. The company's value proposition is centered on addressing significant unmet medical needs through a portfolio of approved treatments and a diversified pipeline of small molecules and biologics. Its primary revenue driver is a leading treatment for tardive dyskinesia and Huntington's disease chorea.
Neurocrine Biosciences (NBIX) has a market capitalization of $15.7B and trades on NASDAQ.
Neurocrine Biosciences generated $3.1B in trailing twelve-month revenue with net income of $668.6M, representing a net margin of 21.6%. Gross margin stands at 98.2%, with free cash flow of $831.3M. These figures are based on the Q1 2026 filing.
Neurocrine Biosciences's key competitors include Bristol-Myers Squibb, Biogen Inc. Common Stock, Roivant Sciences Ltd. Common Shares, and others. These companies compete in similar markets and product categories.
Neurocrine Biosciences has approximately 1,448 employees.